- Canada's Hyal Pharmaceutical has reported a net loss of C$7.04 million ($5.12 million) or C$0.31 per share for the six months ended June 30. This compared to a net loss of C$4.5 million or C$0.25 per share for the same period in 1995. Revenues increased 20% this year from C$1.03 million in 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze